These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 6414690

  • 1. Ifosfamide, mesna and vincristine in paediatric oncology.
    de Kraker J, Voûte PA.
    Cancer Treat Rev; 1983 Sep; 10 Suppl A():165-6. PubMed ID: 6414690
    [No Abstract] [Full Text] [Related]

  • 2. Irreversible encephalopathy with ifosfamide/mesna.
    Salloum E, Flamant F, Ghosn M, Taleb N, Akatchereian C.
    J Clin Oncol; 1987 Aug; 5(8):1303-4. PubMed ID: 3114437
    [No Abstract] [Full Text] [Related]

  • 3. Combination chemotherapy with adriamycin, ifosfamide and mesna in extensive-stage non-small cell bronchogenic carcinoma.
    Matthiessen W, Stempinski E, Göbel D, Thalmann U.
    Cancer Treat Rev; 1983 Sep; 10 Suppl A():121-3. PubMed ID: 6414688
    [No Abstract] [Full Text] [Related]

  • 4. High-dose ifosfamide with mesna uroprotection in Ewing's sarcoma.
    Jürgens H, Exner U, Kühl J, Ritter J, Treuner J, Weinel P, Winkler K, Göbel U.
    Cancer Chemother Pharmacol; 1989 Sep; 24 Suppl 1():S40-4. PubMed ID: 2503258
    [Abstract] [Full Text] [Related]

  • 5. Experience with 24-h infusions of ifosfamide/mesna in small cell lung cancer.
    Cantwell BM, Harris AL, Bozzino JM.
    Cancer Chemother Pharmacol; 1986 Sep; 18 Suppl 2():S29. PubMed ID: 3028660
    [Abstract] [Full Text] [Related]

  • 6. Mitomycin, ifosfamide, and mesna in the treatment of lung cancer.
    Dorr RT.
    Semin Oncol; 1990 Aug; 17(4 Suppl 7):2-5. PubMed ID: 2116668
    [Abstract] [Full Text] [Related]

  • 7. High-dose ifosfamide and mesna in advanced breast cancer. A phase II study.
    Sanchiz F, Milla A.
    Cancer Chemother Pharmacol; 1990 Aug; 26 Suppl():S91-2. PubMed ID: 2112057
    [Abstract] [Full Text] [Related]

  • 8. Full-dose ifosfamide can be safely administered to outpatients.
    Meazza C, Bisogno G, Casanova M, Zanetti I, Carli M, Ferrari A.
    Pediatr Blood Cancer; 2008 Feb; 50(2):375-8. PubMed ID: 16847930
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Ifosfamide/mesna and hematuria.
    Pratt CB, Goren MP.
    Cancer Treat Rep; 1987 Nov; 71(11):1124-5. PubMed ID: 3119210
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. High-dose ifosfamide and mesna as continuous infusion over five days--a phase I/II trial.
    Klein HO, Wickramanayake PD, Coerper C, Christian E, Pohl J, Brock N.
    Cancer Treat Rev; 1983 Sep; 10 Suppl A():167-73. PubMed ID: 6414691
    [No Abstract] [Full Text] [Related]

  • 16. Toxicity and response to high-dose ifosfamide + mesna as salvage therapy for advanced breast cancer.
    Steger GG, Dittrich C, Schlappack O, Mader R, Herold C, Brade WP, Keller A, Moser K.
    J Cancer Res Clin Oncol; 1988 Sep; 114(6):602-4. PubMed ID: 3144554
    [Abstract] [Full Text] [Related]

  • 17. Ifosfamide and mesna at high doses for the treatment of cancer of the cervix: a GETLAC study.
    Cervellino JC, Araujo CE, Pirisi C, Sanchez O, Brosto M, Rossi R.
    Cancer Chemother Pharmacol; 1990 Sep; 26 Suppl():S1-3. PubMed ID: 2112052
    [Abstract] [Full Text] [Related]

  • 18. A prospective randomized evaluation of three schedules of mesna administration in patients receiving an ifosfamide-containing chemotherapy regimen: sustained efficiency and simplified administration.
    Katz A, Epelman S, Anelli A, Gorender EF, Cruz SM, Oliveira RM, Marques LA.
    J Cancer Res Clin Oncol; 1995 Sep; 121(2):128-31. PubMed ID: 7883776
    [Abstract] [Full Text] [Related]

  • 19. Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies.
    Sutton GP, Blessing JA, Photopulos G, Berman ML, Homesley HD.
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):68-72. PubMed ID: 2539647
    [Abstract] [Full Text] [Related]

  • 20. Experience of the Belgian Society of Medical Oncology with single-administration 5 g/m2 ifosfamide with mesna as second- or third-line therapy in advanced breast cancer.
    Paridaens R, Focan C, Michel J, Piccart M, Salamon E, Beauduin M, Closon MT, Tueni E, Vindevoghel A, Majois F.
    Cancer Chemother Pharmacol; 1990 Feb; 26 Suppl():S63-5. PubMed ID: 2112055
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.